Generalized epilepsy with febrile seizures plus
MONDO:0018214A familial epilepsy syndrome in which family members display a seizure disorder from the generalized epilepsy with febrile seizures plus spectrum which ranges from simple febrile seizures (FS) to the more severe phenotype of myoclonic-astatic epilepsy (MAE) or Dravet syndrome (DS).
Also known as: GEFS+, epilepsy, generalized, with febrile seizures plus, generalised epilepsy with febrile seizures-plus, generalized epilepsy with febrile seizures plus, genetic epilepsy with febrile seizures plus, genetic epilepsy with febrile seizures-plus
11 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy trial aims to tame severe seizures in kids with dravet syndrome
Disease control OngoingThis study tests a gene therapy called ETX101 in 4 children with Dravet syndrome, a severe seizure disorder caused by a gene change. The therapy uses a harmless virus to deliver a working copy of the gene to brain cells. The main goals are to see if it is safe and if it reduces s…
Phase: PHASE1, PHASE2 • Sponsor: Encoded Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief ENROLLING_BY_INVITATIONThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New hope for rare burning pain: drug trial targets genetic cause
Symptom relief ENROLLING_BY_INVITATIONThis early-stage study tests whether BHV-7000 can reduce chronic pain in people with inherited erythromelalgia, a rare condition causing severe burning pain due to a genetic mutation. Only 5 adults with a specific NaV1.7 mutation will participate, comparing the drug to a placebo …
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC